Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 04 04:00PM ET
89.84
Dollar change
+0.33
Percentage change
0.37
%
IndexNDX, S&P 500 P/E109.80 EPS (ttm)0.82 Insider Own0.21% Shs Outstand1.25B Perf Week1.22%
Market Cap111.85B Forward P/E12.36 EPS next Y7.27 Insider Trans-2.57% Shs Float1.24B Perf Month6.21%
Income1.05B PEG17.46 EPS next Q1.51 Inst Own84.89% Short Float1.33% Perf Quarter21.09%
Sales27.78B P/S4.03 EPS this Y-43.49% Inst Trans-0.02% Short Ratio2.70 Perf Half Y37.08%
Book/sh14.67 P/B6.12 EPS next Y91.33% ROA1.82% Short Interest16.48M Perf Year10.60%
Cash/sh3.37 P/C26.64 EPS next 5Y6.29% ROE5.34% 52W Range62.07 - 89.74 Perf YTD10.90%
Dividend Est.3.08 (3.42%) P/FCF16.22 EPS past 5Y1.55% ROI2.64% 52W High0.11% Beta0.19
Dividend TTM3.06 (3.41%) Quick Ratio0.95 Sales past 5Y4.16% Gross Margin77.60% 52W Low44.74% ATR (14)1.42
Dividend Ex-DateSep 13, 2024 Current Ratio1.14 EPS Y/Y TTM-80.78% Oper. Margin36.44% RSI (14)69.87 Volatility1.56% 1.57%
Employees18000 Debt/Eq1.28 Sales Y/Y TTM2.05% Profit Margin3.79% Recom1.97 Target Price88.58
Option/ShortYes / Yes LT Debt/Eq1.18 EPS Q/Q55.31% Payout66.62% Rel Volume1.00 Prev Close89.51
Sales Surprise3.75% EPS Surprise25.05% Sales Q/Q5.46% EarningsNov 06 AMC Avg Volume6.11M Price89.84
SMA202.94% SMA506.94% SMA20021.09% Trades Volume6,124,270 Change0.37%
Date Action Analyst Rating Change Price Target Change
Oct-21-24Upgrade Leerink Partners Market Perform → Outperform $74 → $96
Oct-17-24Initiated Bernstein Outperform $105
Oct-07-24Upgrade Wells Fargo Equal Weight → Overweight $78 → $100
Jul-08-24Upgrade Raymond James Mkt Perform → Outperform $93
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Nov-04-24 05:53PM
Nov-03-24 07:00AM
Nov-01-24 09:15AM
Oct-31-24 05:50PM
09:00AM
06:00AM Loading…
06:00AM
Oct-30-24 10:01AM
Oct-29-24 06:00PM
Oct-24-24 08:15AM
Oct-23-24 06:00PM
Oct-22-24 12:36PM
09:00AM
Oct-21-24 12:28PM
Oct-19-24 05:09PM
11:57AM
02:34PM Loading…
Oct-18-24 02:34PM
08:50AM
Oct-17-24 09:00AM
Oct-15-24 06:00PM
Oct-14-24 10:01AM
Oct-10-24 07:22PM
Oct-09-24 05:52PM
04:05PM
08:30AM
Oct-08-24 06:00PM
09:25AM
Oct-07-24 11:00AM
02:52AM
Oct-03-24 09:00AM
04:52AM
10:43AM Loading…
Oct-02-24 10:43AM
08:30AM
Oct-01-24 06:00PM
Sep-25-24 09:55AM
Sep-24-24 06:00PM
Sep-23-24 04:06PM
02:12PM
09:38AM
Sep-21-24 12:00PM
07:36AM
Sep-19-24 09:00AM
Sep-18-24 01:30PM
Sep-17-24 06:00PM
Sep-16-24 06:00AM
01:52AM
Sep-14-24 08:45AM
01:51AM
Sep-13-24 06:55AM
Sep-12-24 06:11PM
04:05PM
01:46PM
10:20AM
10:07AM
09:45AM
09:35AM
08:30AM
Sep-11-24 05:50PM
03:52AM
Sep-10-24 09:20AM
08:00AM
Sep-08-24 01:57AM
Sep-06-24 09:15AM
Sep-05-24 08:00AM
Sep-04-24 09:25AM
06:52AM
Aug-30-24 05:34PM
02:05PM
01:46AM
Aug-28-24 06:19PM
Aug-27-24 09:15AM
Aug-26-24 01:19PM
Aug-22-24 09:00AM
Aug-21-24 04:05PM
Aug-20-24 02:00PM
09:00AM
08:30AM
Aug-19-24 05:12AM
Aug-17-24 01:44AM
Aug-15-24 01:13PM
09:09AM
06:53AM
Aug-14-24 05:01PM
01:59PM
Aug-13-24 08:45AM
Aug-10-24 06:50AM
Aug-09-24 04:34PM
04:11PM
02:43PM
12:22PM
11:15AM
09:45AM
08:23AM
06:52AM
01:12AM
Aug-08-24 09:45PM
06:00PM
05:16PM
05:15PM
04:20PM
04:12PM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parsey MerdadChief Medical OfficerOct 01 '24Sale83.832,000167,660100,189Oct 02 04:58 PM
MERDAD V PARSEYOfficerOct 01 '24Proposed Sale83.832,000167,660Oct 01 04:27 PM
Parsey MerdadChief Medical OfficerSep 12 '24Option Exercise57.9225,0001,448,000123,435Sep 13 07:07 PM
Parsey MerdadChief Medical OfficerSep 12 '24Sale84.5021,2461,795,287102,189Sep 13 07:07 PM
Mercier JohannaChief Commercial OfficerSep 12 '24Sale83.7829,3572,459,57778,127Sep 13 05:08 PM
MERDAD V PARSEYOfficerSep 12 '24Proposed Sale84.5021,2461,795,287Sep 12 04:45 PM
JOHANNA MERCIEROfficerSep 12 '24Proposed Sale83.7829,3572,459,577Sep 12 04:43 PM
Mercier JohannaChief Commercial OfficerAug 28 '24Sale78.039,513742,299105,466Aug 29 03:23 PM
JOHANNA MERCIEROfficerAug 28 '24Proposed Sale78.039,513742,299Aug 28 04:18 PM
Mercier JohannaChief Commercial OfficerAug 13 '24Sale73.985,490406,150114,979Aug 14 02:23 PM
JOHANNA MERCIEROfficerAug 13 '24Proposed Sale73.985,490406,150Aug 13 04:27 PM
Parsey MerdadChief Medical OfficerJul 01 '24Sale68.632,000137,26096,380Jul 01 08:06 PM
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM